These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1025 related articles for article (PubMed ID: 12499267)

  • 1. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes.
    Ahlers JD; Dunlop N; Alling DW; Nara PL; Berzofsky JA
    J Immunol; 1997 Apr; 158(8):3947-58. PubMed ID: 9103465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.
    Chen SH; Pham-Nguyen KB; Martinet O; Huang Y; Yang W; Thung SN; Chen L; Mittler R; Woo SL
    Mol Ther; 2000 Jul; 2(1):39-46. PubMed ID: 10899826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
    Lechanteur C; Moutschen M; Princen F; Lopez M; Franzen E; Gielen J; Bours V; Merville MP
    Cancer Gene Ther; 2000 May; 7(5):676-82. PubMed ID: 10830715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA; Taylor PA; Aukerman SL; Blazar BR
    Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of fusion gene mGM-CSF/hIL-2 to specific immunotherapy induced by hepatic tumor cell vaccine].
    Yang W; Guo C; Liu QG
    Ai Zheng; 2008 Feb; 27(2):149-54. PubMed ID: 18279611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.